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 ABSTRACT 
Glycosylation is one of the most common and structurally diverse post-
translational modifications of proteins. Given that protein glycosylation is 
involved in various cellular processes, the characterization of site-specific 
N- and O-linked glycosylations is becoming increasingly important. 
However, current mass spectrometry-based technologies, i.e. proteomics 
and glycomics, are unable to resolve the site-specific glycosylation pattern 
of glycoproteins.  
The primary aim of this thesis was to develop glycoproteomic techniques 
for mass spectrometric analysis of glycoproteins. A sialic acid capture-
and-release method, based on hydrazide chemistry, for selective 
enrichment of N- and O-linked glycopeptides from complex biological 
samples was developed. Enriched glycopeptides were separated by 
reversed phase liquid chromatography and analyzed by Fourier transform 
ion cyclotron mass spectrometry (FTICR MS) utilizing collision induced 
dissociation (CID) and electron capture dissociation (ECD) fragmentation 
techniques.  
Initially, both N- and O-glycopeptides from sialylated glycoproteins of 
human cerebrospinal fluid (CSF) were enriched and characterized. 
Subsequently, a targeted O-glycoproteomics approach was developed, 
allowing for sequence analysis of preferred O-glycosylation sites of 
glycoproteins. The applicability of the sialic acid capture-and-release 
strategy was further demonstrated for human urine, a technically more 
challenging biological fluid. The LC-MS/MS analyses revealed unique N- 
and O-glycosylations, many of which were previously unknown, both for 
CSF and urinary glycoproteins. In e.g. CSF, a series of O-glycopeptides 
with Thr linked O-glycans in the vicinity of the β-secretase cleavage site 
of the amyloid precursor protein (APP) were identified. Additionally, 
amyloid beta (Aβ) peptides, originating from APP, were 
immunoprecipitated from CSF samples for a targeted glycoproteomic 
analysis. These analyses revealed that a series of Aβ peptides were 
uniquely modified with sialylated O-glycans at a specific Tyr residue. A 
relative increase of such Tyr O-glycosylated Aβ peptides was observed in 
CSF samples from Alzheimer’s disease (AD) patients compared to non-
AD patients, suggesting that these Aβ glycopeptides may potentially be 
used as biomarkers of AD.    
Keywords: Glycobiology, Glycoproteomics, Mass spectrometry 
ISBN: 978-91-628-8412-3 
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Glykoproteiner är en särskild klass av proteiner som fyller många och 
skiftande funktioner i levande organismer. Glykoproteiner har olika typer 
av sockerstrukturer, även kallade glykaner, bundna till specifika 
aminosyror, vanligtvist till asparagin (N-glykaner) eller till serin/treonin 
(O-glykaner). Glykoproteinernas strukturer behöver kartläggas i detalj för 
att vi ska få en bredare förståelse av deras roller i fundamentala biologiska 
processer. Proteomikstudier har blivit ett väletablerat tillvägagångssätt för 
studier av alla samtidigt förekommande proteiner i komplexa biologiska 
blandningar och genom dessa kan man idag identifiera tusentals proteiner 
från enstaka prover. Många av dessa proteiner är glykoproteiner men 
information om de bundna glykanerna är ofta bristfällig och kräver 
särskild metodologi. Glykomik är en sådan kompletterande teknik för 
massspektrometrisk (MS) analys av glykaner. Specifik information om 
glykosylering erhålls vanligen då man, kemiskt eller enzymatiskt, 
separerar glykanerna ifrån proteinerna och studerar dessa sockerstrukturer 
separat. Dessa metoder ger god strukturell information om förekommande 
glykaner och proteiner men begränsas av att man inte kan ange exakt vilka 
enskilda glykaner som sitter bundna till vilka enskilda aminosyror på 
respektive protein.  
Glykoproteomik är ett nytt forskningsfält där intakta glykopeptider, dvs. 
proteinfragment med kvarvarande glykaner, analyseras. Hittills har 
glykoproteomikstudier varit begränsade till analys av enskilda proteiner, 
mycket på grund av brist på effektiva anrikningsmetoder för 
glykoproteiner och glykopeptider. Det övergripande målet med denna 
avhandling har varit att utveckla nya metoder som möjliggör MS-baserade 
strukturstudier av glykopeptider avspjälkade från glykoproteiner anrikade 
ur komplexa biologiska prover.  
Vår anrikningsstrategi baseras på en enkel kemisk modifiering av en 
speciell sockerstruktur, sialinsyra som är vanligt förekommande på många 
olika glykoproteiner, för att skapa reaktiva grupper som sedan kan 
utnyttjas för att koppla glykoproteinerna till kemiskt aktiverade plastkulor 
och därmed anrika dessa glykoproteiner på en fast yta. Genom att tvätta 
bort ospecifikt bundna proteiner kan de sialinsyreinnehållande 
glykoproteinerna anrikas selektivt. Efter klyvning av de bundna 
proteinerna t.ex. med enzymet trypsin, vilket generar många fragment av 
lämplig storlek för MS-analys, kan de kvarvarande glykopeptiderna 
selektivt frigöras från plastkulorna med mild syrabehandling. De frigjorda 
 glykopeptider, utan kvarvarande sialinsyror, kan därefter analyseras med 
MS.  
Metoden tillämpades först på ryggmärgsvätska (CSF) och även om denna 
mängdmässigt domineras av albumin, som inte är ett glykoprotein, kunde 
vi effektivt anrika många olika glykoproteiner och karaktärisera deras N- 
och O-glykopeptider. Därefter förfinade vi tekniken för att möjliggöra 
riktad analys av enbart O-glykopeptider. Genom att inkludera en 
enzymatisk förbehandling, med PNGase F, som specifikt spjälkar alla 
glykaner kopplade till aminosyran asparagin kunde ännu fler O-
glykopeptider från CSF anrikas, analyseras och identifieras. 
Anrikningsmetoden tillämpades framgångsrikt även på urin, som är ett 
tekniskt mer utmanande biologiskt utgångsmaterial. Metoden tillät oss att 
studera glykaner och deras kopplingar till olika aminosyror på enskilda 
anrikade glykopeptider, vilket inte är möjligt med tekniker som proteomik 
och glykomik. I dessa studier kunde vi beskriva flera tidigare okända 
glykosyleringar, framförallt O-glykosyleringar, och också dra slutsatser 
om vilka aminosyra-sekvenser som företrädesvis blir glykosylerade i den 
levande vävnaden (in vivo). 
Många intressanta nya O-glykopeptider identifierades, bl.a. en 
glykopeptid, anrikad från CSF, som härstammar från amyloid prekursor 
proteinet (APP). Felaktig nedbrytning av APP i hjärnan ger en ökning av 
amyloid beta (Aβ) peptider som är giftiga för nervceller och som genom 
att aggregera bildar s.k. amyloida plack. Dessa amyloida plack tror man är 
avgörande för utvecklingen av Alzheimers sjukdom (AD). Med hjälp av 
antikroppar riktade emot APP kunde vi anrika APP/Aβ peptider ur CSF 
och med vår MS-analys påvisa att flera av dessa även var 
O-glykosylerade, vilket inte var känt sedan tidigare. Dessutom 
identifierade vi Aβ peptider med sialinsyreinnehållande O-glykaner bunda 
till tyrosin (Tyr), vilket inte setts tidigare i något mänskligt protein. En 
relativ ökning av dessa glykosylerade Aβ peptider observerades hos AD 
jämfört med icke-AD patienter vilket antyder att Tyr-glykosylerade Aβ 
peptider skulle kunna användas för tidig diagnostik av AD. 
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1 INTRODUCTION 
1.1 Glycobiology 
The principal building blocks in all cells are nucleic acids, lipids, proteins 
and carbohydrates [1]. In medicine, biochemistry and other related areas, 
carbohydrates are perhaps best known as molecules that store energy and fuel 
cellular metabolism. However, carbohydrates, or glycans, are also key 
components of various structural elements that are of central importance for 
cellular function and viability.  
Remarkably, all living cells are covered with a dense layer of glycans  [2]. 
This complex network, also known as the glycocalyx, is composed of free 
glycans and different types of glycoconjugates, i.e. oligosaccharides that are 
covalently attached to proteins or lipids. Oligosaccharides may exhibit an 
enormous structural complexity due to the variability of linkage positions and 
anomeric configurations that may connect epimeric monosaccharides in 
linear or branched sequences. Embedded in this complexity is a capacity to 
store biological information which, at least in theory, may exceed the storage 
capacity of other biopolymers, e.g. oligonucleotides and polypeptides [3]. It 
is therefore not surprising that every living organism has found a way to 
utilize glycans and glycan binding proteins to encode and decipher cellular 
information [4]. 
Although the basic questions of carbohydrate chemistry were elucidated very 
early, the modern understanding of glycan biosynthesis and molecular 
biology was not clarified until the second half of the 20
th
 century. In fact, the 
specific term glycobiology surfaced for the first time in the late 1980s [5]. 
This scientific branch is engaged in the study of glycan- and glycoconjugate 
structures, glycan binding proteins (lectins), glycan biosynthesis, metabolism, 
evolution and biology in health and disease. 
1.1.1 Glycans 
Basic structural units of glycans 
Monosaccharides are aldehydes or ketones with multiple hydroxyl groups. 
One of the simplest monosaccharides is glyceraldehyde with three carbon 
atoms, referred to as triose, and two hydroxyl groups. The general formula 
(C-H2O)n is applicable for most monosaccharides and literally means 
“hydrated carbon”. Monosaccharides with six carbon atoms, or hexoses, are 
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typically found as constituents of glycoconjugates. Although the connecting 
order of atoms in a monosaccharide may be the same, the geometrical 
orientation of hydroxyl groups might be different, giving rise to 
stereoisomers, e.g. glucose (Glc), galactose (Gal) and mannose (Man) [6]. 
These hexoses, together with their N-acetamido derivatives N-
acetylgalactosamine (GalNAc) and N-acetylglucosamine (GlcNAc), are some 
of the basic building blocks of vertebrate glycans. A special family of 
negatively charged, 9 carbon monosaccharides, termed N-acetylneuraminic 
acid (Neu5Ac) or just sialic acid (Sia), are typically found at terminal 
positions of glycans (see below) [7, 8]. Additional constituents of glycans 
include fucose (Fuc), xylose (Xyl), glucuronic acid (GlcA) and iduronic acid 
(IdoA) [9].   
Monosaccharides have a tendency to form cyclic structures in solution. This 
process involves the reaction of a hydroxyl group with the C-1 aldehyde or 
ketone, resulting in the formation of a hemiacetal group. Any of the anomeric 
forms, designated α and β, may result from this reaction (Fig. 1) [10]. 
Figure 1. The D-glucose hemiacetals are shown as α- and β anomers (top). The 
structure of N-acetyllactosamine (LacNAc) is shown (bottom).   
1 
2 
3 
4 
5 
6 
α-D-Glucose β-D-Glucose 
(Galβ1-4GlcNAcβ) 
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The anomeric carbon of one monosaccharide may be joined with the 
hydroxyl group of another. This reaction (enzymatically catalyzed, see 
below) forms the O-glycosidic bond that links monomeric units into 
oligosaccharides. Exemplified in Fig. 1, the anomeric C-1 of Gal has been 
combined with the C-4 hydroxyl group of GlcNAc, resulting in the formation 
of typical disaccharide found in glycans, namely Galβ1-4GlcNAc (LacNAc). 
According to this principle, stereoisomers may be linked as α- or β anomers 
at different positions to form numerous linear or branched glycans. Each 
structure is considered to be a unique epitope with a potentially distinct 
biological activity.  
Glycan biosynthesis 
The primary synthesis of glycans is orchestrated by the endoplasmic 
reticulum (ER) and Golgi associated glycosyltransferases. These enzymes 
catalyze the transfer of activated monosaccharides, or nucleotide sugar 
donors, to acceptor substrates, e.g. lipids, proteins or other glycans. Most 
monosaccharides are activated as uridine-diphosphate (UDP) sugars, e.g. 
UDP-Glc, UDP-Gal, and UDP-GalNAc. The only monosaccharides that 
deviate from this rule are Fuc, Man and Neu5Ac, which are found as 
guanosine-diphosphate (GDP-Fuc and GDP-Man) or as cytidine-
monophosphate (CPM-Neu5Ac) sugars [9]. Each nucleotide donor sugar is 
recognized by a specific family of glycosyltransferases, of which each family 
member is able to catalyze a specific reaction between donor and acceptor 
substrates. Glycan biosynthesis can therefore be generalized according to the 
“one enzyme-one linkage” hypothesis, i.e. a specific nucleotide donor sugar 
is linked to a specific acceptor substrate in one particular anomeric 
configuration and linkage position [11]. Following synthesis, glycans may 
also be trimmed (by various glycosidases) or further modified by e.g. 
phosphorylation, sulfation or acetylation [12-15]. Collectively, these 
processes are able to produce highly complex glycan structures [16].  
Glycoconjugates 
Molecules composed of glycans that are covalently and enzymatically 
attached to non-carbohydrate units are generally classified as 
glycoconjugates. Glycoconjugates are widely distributed in biological fluids, 
cellular membranes and intracellular compartments. This large family of 
molecules includes e.g. glycoproteins, proteoglycans, glycosphingolipids, 
glycosylphosphatidylinositol (GPI) anchored proteins and glucuronides. 
However, the discussion will from here on only focus on the concepts of 
glycoproteins, their biosynthesis, structures and functions.   
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1.1.2 Glycoproteins 
N-linked glycoproteins 
Glycoproteins are usually categorized according to the nature of the linkage 
by which the glycans are attached. For N-linked glycoproteins, or simply just 
N-glycoproteins, the oligosaccharide component is linked to the side chain 
amide nitrogen (N) atom of asparagine residues (Asn), hence the names N-
glycan and N-glycoprotein. Although other forms exist, GlcNAcβ1-N-Asn 
represents the most common type of N-glycosidic linkage to proteins [17].  
N-glycan biosynthesis is initiated in the ER by the en bloc transfer of a 
preassembled Glc3Man9GlcNAc2 moiety from a dolichol-pyrophosphate lipid 
anchor to newly synthesized proteins. The asparagine residue can accept the 
Glc3Man9GlcNAc2 moiety only if it is part of an asparagine-X-
serine/threonine/cysteine consensus sequence (Asn-X-Ser/Thr/Cys), where X 
is any amino acid except proline (Pro) [18, 19]. Following transfer to an Asn 
residue, the oligosaccharide is processed by specific glycosidases that 
hydrolyze individual glycosidic bonds of the 14-sugar glycan. The 
monoglucosylated Glc1Man9GlcNAc2 intermediate, which is recognized by 
the lectin-like ER chaperones calnexin (CNX) and calreticulin (CRT), plays a 
central role in protein quality control and folding [20, 21]. Properly folded N-
glycoproteins are subsequently translocated to the Golgi compartments and 
processed by various glycosidases and glycosyltransferases to produce one of 
three different types of N-glycan structures, i.e. complex, hybrid or high-
mannose.  
Each type consists of a core Man3GlcNAc2 glycan with at least two branched 
glycan chains, also known as antennas. The three different N-glycan types are 
classified according to the sugar composition of the antennae. Complex type 
N-glycan antennas are composed of different monosaccharides (Fig. 2), e.g. 
Neu5Acα2-6Galβ1-4GlcNAcβ2Man, whereas high-mannose type N-glycans 
contain only Man units on both antennas. Hybrid type N-glycans are a 
combination of high-mannose and complex N-glycans [22].  
The final step of maturation occurs in the late Golgi compartments where 
most N-linked oligosaccharides are converted to complex type N-glycans 
before the glycoprotein is secreted or translocated to the plasma membrane. 
In humans, complex type N-glycans constitute the dominating glycoform of 
secreted N-glycoproteins [23].  
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The complex type N-glycans represent a heterogeneous mixture of structures 
that accommodate not only other monosaccharides (e.g. Fuc or GalNAc) but 
also include sulfate or phosphate modifications. The structural diversity of 
these glycans is further extended by the addition of three (tri-antennary) or 
four (tetra-antennary) antennas with terminal Neu5Ac units. Consequently, 
the population of a single glycoprotein may comprise several unique N-
glycan structures, situated at one or multiple Asn-X-Ser/Thr/Cys N-
glycosylation sites. The number of complex type N-glycans can therefore 
exceed 150 different structures for individual glycoproteins [24]. 
 
O-linked glycoproteins 
The covalent attachment of glycans to the hydroxyl groups of Ser and Thr 
residues constitutes the structural basis of O-linked glycoproteins (O-
glycoproteins). Protein linked O-glycans can be initiated through many 
different monosaccharides but the most abundant and complex form of O-
glycosylation is generally attributed to the mucin-type GalNAcα-O-Ser/Thr 
glycans [25]. In contrast to N-glycans, mucin-type O-glycans lack a common 
core structure and are all elongated from a single monosaccharide to form 
eight different core structures (table 1) [26]. The simplest mucin-type glycan, 
sometimes referred to as the Tn antigen, is thus GalNAcα-O-Ser/Thr. This 
single monosaccharide is transferred from UDP-GalNAc to Ser/Thr residues 
by the action of polypeptide-N-acetylgalactosaminyltransferases 
(ppGalNAcT) [27].  
Figure 2. Secreted and membrane bound glycoproteins. 
Thr 
Thr 
Ser 
Asn 
Asn 
Blood group A 
antigen 
SLeX epitope 
Triantennary 
N-glycan 
Core 2 
O-glycan 
Core 1 
O-glycan 
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Table 1. Core structures of mucin-type O-glycans. 
O-Glycan Structure 
Tn-antigen GalNAcα-O-Ser/Thr 
Core 1 (T antigen) Galβ1-3GalNAcα-O-Ser/Thr 
Core 2 GlcNAcβ1-6(Galβ1-3)GalNAcα-O-Ser/Thr 
Core 3 GlcNAcβ1-3GalNAcα-O-Ser/Thr 
Core 4 GlcNAcβ1-6(GlcNAcβ1-3)GalNAcα-O-Ser/Thr 
Core 5 GalNAcα1-3GalNAcα-O-Ser/Thr 
Core 6 GlcNAcβ1-6GalNAcα-O-Ser/Thr 
Core 7 GalNAcα1-6GalNAcα-O-Ser/Thr 
Core 8 Galα1-3GalNAcα-O-Ser/Thr 
 
The enzyme family consists of at least 20 members, ppGalNAcT-1 to -20, 
that differ in the ability to recognize and glycosylate their polypeptide 
substrates [25, 28]. Contrary to N-glycosylation, mucin-type O-glycosylation 
lacks a consensus peptide sequence although these O-glycans are generally 
found in protein regions rich in Ser, Thr and Pro residues [29]. 
In the majority of tissues, the second step of mucin-type O-glycan synthesis 
involves the addition of Gal to the Tn antigen, resulting in the formation of 
core 1 O-glycans (T antigen) [30]. This specific step is performed by T-
synthase and requires the molecular chaperone Cosmc for activity in the 
Golgi compartment [29, 31]. The core 1 O-glycan biosynthesis is usually 
terminated by the addition of two Neu5Ac units at C-3 of Gal and C-6 of 
GalNAc. This reaction may be catalyzed by several enzymes of the 
sialyltransferase (ST) family, e.g. ST3Gal I and ST6GalNAc I members [29]. 
The outcome of this pathway results in the formation of di-sialylated core 1 
O-glycans (Fig. 3).  
Thr Thr Thr Thr 
Figure 3. Biosynthesis of di-sialylated core 1 O-glycan. 
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Alternatively, the Tn and T antigens may be modified by GlcNAc prior to the 
addition of Neu5Ac to form core structures 2, 3 or 4. Core 2 O-glycans are 
found in most tissues whereas core 3 and core 4 O-glycans are prominent 
structures on the mucus epithelia of the gastrointestinal and respiratory tracts 
[29, 32-36]. Core structures 5-8 are rare and the enzymatic processes that 
generate these O-glycans are essentially unknown [25].  
Core structures 2-4 are typically elongated to complex O-glycan structures by 
the addition of repeating disaccharides, e.g. poly-LacNAc (Fig. 1), or other 
biologically active epitopes. The synthesis of complex O-glycans is usually 
terminated by the addition of histo-blood group antigens or terminal sialic 
acids (Fig. 2) [29]. 
Biological roles of N- and O-linked glycans 
Although N- and O-linked glycans have different core structures and protein 
attachment sites, the true structural diversity and biological activity is often 
found at terminal positions of these glycans. Secreted and membrane bound 
N- and O-glycoproteins are typically decorated with Neu5Acα2-3Galβ-R or 
Neu5Acα2-6Galβ-R epitopes that are utilized as ligands by various 
endogenous lectins. These interactions include intrinsic recognitions by 
Siglecs (I-type lectins) in e.g. cell-cell communications and signaling events 
of the immune, haemopoietic and nervous systems [37, 38]. Terminal sialic 
acids are also important constituents of larger epitopes, e.g. the Neu5Acα2-
3Galβ1-4(Fucα1-3)GlcNAcβ-R glycan, also known as the sialyl-Lewis
X
 
(SLe
X
) determinant (Fig. 2). Together with its binding partners E-, L- and P-
selectins, the SLe
X
 epitope participates in leukocyte-endothelial cell 
adhesions and plays a key role in the inflammatory response process [39, 40].  
Heterogeneous structures of branched and elongated mucin-type O-glycans 
are usually found in Pro, Ser and Thr rich protein domains of secreted and 
membrane bound mucins. These clusters of hydrophilic and negatively 
charged O-glycans are able to bind H2O and form a viscous coat that 
lubricates and protects the underlying tissue against chemical and microbial 
insult [25, 29, 41, 42]. Mounting evidence also suggests that single, sialylated 
core 1 O-glycans located at specific Ser/Thr residues adjacent to enzymatic 
cleavage sites are able to suppress proteolytic processing of proteins [26, 28, 
43-45]. Proprotein convertase (PC) processing, responsible for producing 
active neuronal and endocrine hormones by regulated proteolysis of secretory 
proteins [46], has also been shown to be co-regulated by site-specific O-
glycosylations [47-49].    
Targeting the human glycoproteome 
8 
The ABO(H) blood group system is perhaps the most illustrative example of 
a specific biological consequence of glycans. These determinants are 
composed of a common Fucα1-2Galβ-R structure, i.e. the H antigen, and are 
typically found as terminal epitopes on glycosphingolipids and N- and O-
linked glycans (Fig. 2) [16, 50-52]. Depending on the genetic background of 
the individual, the terminal Fucα1-2Galβ-R disaccharide may be branched as 
GalNAcα1-3(Fucα1-2)Galβ-R (A antigen), as Galα1-3(Fucα1-2)Galβ-R (B 
antigen) or remain unmodified (H antigen). These structures are of central 
importance for inter-individual blood transfusions and organ transplantation 
procedures. 
However, the glycans described above represent only a few, selected 
examples of biologically active epitopes. Many other functional roles have 
been assigned to protein linked glycans and the biological significance of 
some oligosaccharides are still unknown [53]. Akin to “junk”  DNA, there 
are presently also “junk” glycans with no apparent biological activity [54]. 
Depending on type, the biological role of a given glycan may thus be vital or, 
as yet, not fully understood.  
1.2 Mass spectrometry 
Mass spectrometry (MS) is one of the most important analytical techniques in 
structural glycobiology [55]. The principles of MS are based on ionization of 
molecules, separation of gas-phase ions and detection of these charged 
species according to their mass-to-charge ratio (m/z). Thus, in its most basic 
form, MS can be used to determine the mass of a given analyte. However, 
modern MS instruments are also able to dissociate ionized molecules 
(precursor ions) and mass measure the resulting fragments (product ions). 
This process, referred to as tandem MS, MS/MS or MS
2
, can therefore be 
used to elucidate the primary structure (sequence) of peptides, glycans or 
glycopeptides.  
Although the design and configuration may vary considerably, all MS 
instruments are composed of three primary components, i.e. an ion source, a 
mass analyzer and a detector. The ion source generates gas-phase ions, an 
absolute requirement in MS, from nonvolatile, thermally labile analytes, e.g. 
proteins or peptides. The most common ionization mechanisms of modern 
mass spectrometers are matrix-assisted laser desorption/ionization (MALDI) 
and electrospray ionization (ESI) [56, 57]. The characteristic behavior of 
charged particles in electric/magnetic fields allows the mass analyzer to 
separate specific ions according to their m/z ratio. Many modern MS 
instruments have e.g. time-of-flight (TOF), linear ion trap quadrupole (LTQ), 
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Fourier transform ion cyclotron resonance (FTICR) or orbitrap mass 
analyzers. The ion detection process is usually amplified by a separate 
electron multiplier (EM) or recorded as an image-current (frequency) by the 
mass analyzer itself (for FTICR and orbitrap) [58]. Regardless of 
instrumental design and configuration, the MS data is always presented as a 
mass spectrum, i.e. a plot of ion intensities (y-axis) vs. ion m/z values (x-
axis).  
In addition, two separate mass analyzers, e.g. LTQ and FTICR, may be 
combined in the same instrument for optimal performance. The resulting 
hybrid mass spectrometer may also be interfaced with a high performance 
liquid chromatography (HPLC) system to facilitate the analysis of complex 
biological samples. In the remaining part of this thesis, the principles and 
applications of ESI-LTQ-FTICR MS, a hybrid mass spectrometer used to 
collect the MS data of this thesis, will be described in more detail. 
1.2.1 ESI-LTQ-FTICR mass spectrometry 
Electrospray ionization 
The underlying theory for dissipating a liquid sample as a homogeneous 
electrospray was formulated during the 1960s by Sir Geoffrey Taylor and, 
shortly after, Dole and coworkers speculated that electrospray could be used 
as a technique to generate molecular beams of larger molecules [59, 60]. 
However, it was not until the late 1980s that ESI of proteins was shown to be 
possible [57, 61].  
ESI is initiated when a potential is applied to the edge of a capillary. The 
electrostatic force pulls the liquid towards the tip of the capillary and causes 
it to adopt an elliptic shape. At a certain voltage, the curvature of the ellipse 
collapses into a cone, also known as a Taylor cone, resulting in the formation 
of a spray that starts to emit fine droplets of liquid [62]. Depending on the 
polarity of the applied potential, the droplets may contain either positively or 
negative charged molecules. While in flight, the droplets shrink in size by 
evaporation of neutral solvent particles [63], a process that proceeds until 
multiply charged molecular ions are formed at atmospheric pressure [64]. 
Although the exact mechanism is still a matter of debate, two models have 
emerged to explain the details of ESI, namely the ion evaporation model [65, 
66] and the charge residue model [60, 62].  
ESI offers many advantages to MS-based analysis of biomolecules. Because 
it ionizes molecules directly from the liquid phase, the ESI ion source may be 
coupled to an HPLC system to produce gas-phase ions during the 
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chromatographic separation (on-line HPLC-MS) of e.g. peptides or glycans.  
ESI is also considered to be a “soft ionization” technique able to generate 
molecular ions without compromising the integrity of large molecules or 
protein complexes [67]. These properties, together with the high efficiency 
(up to 100%) of ESI [62, 68], have made this ionization method a popular 
choice in many MS-based analyses.  
LTQ-FTICR mass spectrometry 
Comisarow and Marshall developed the first FTICR mass analyzer [69, 70] 
based on the original ICR MS technique [71]. This method is based on the 
fact that charged particles are manipulated in magnetic fields. More 
specifically, the velocity vector of a charged particle experiences a force, 
referred to as the Lorentz force, when subjected to a perpendicular magnetic 
field. The Lorentz force, which is perpendicular to the plane defined by the 
magnetic field and the velocity vector, therefore causes the charged particle 
to adopt a circular trajectory [72]. Since the magnetic field (B) is constant and 
uniform in FTICR MS, the periodic rotation of the charged particle, which 
can be expressed as a frequency (f), will thus only depend on the mass (m) 
and charge (z) of the particle, according to the equation: 
 = /2 
Given that frequencies can be measured very accurately, a mathematical 
Fourier transform operation may therefore be used to convert the frequency 
of each analyte ion to an accurate mass. The hallmarks of FTICR MS are 
therefore high mass accuracy and high mass resolution [73-75]. 
Although the FTICR mass analyzer is capable of performing tandem MS 
experiments, there is a significant advantage when analyte ions are 
fragmented in a linear ion trap. The LTQ is characterized by e.g. fast 
scanning ability and excellent ion storage capacity which improves the 
overall sensitivity for product ion detection during tandem MS analysis [76]. 
The hybrid LTQ-FTICR mass spectrometer is therefore able to perform 
accurate mass measurements of precursor ions and sensitive detection of 
product ions  [77]. The fragmentation mechanisms of the LTQ and FTICR 
mass analyzers are further described in the methods section.  
1.2.2 MS applications and –omics 
Proteomics 
Proteomics is an MS-based technology that generally deals with the 
identification and characterization of proteins. More specifically, proteomics 
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is defined as the qualitative or quantitative study of the protein expression 
profile in a specific organism, tissue or cell during a specific physiological 
state [78, 79]. A typical proteomics experiment includes a pre-analytical step 
where proteins are initially reduced and alkylated (Cys residues). 
Subsequently, the proteins are digested into peptides by specific proteases, 
e.g. trypsin (cleaves C-terminally to arginine/lysine-X, where X ≠ proline). 
The tryptic peptides are passed through a HPLC system, separated according 
to their physiochemical properties and eluted directly into the ESI ion source. 
The on-line HPLC approach allows a subset of peptides to be analyzed 
during each time interval of the chromatography, thereby increasing the 
overall sensitivity of the analysis [80]. At a given retention time, peptides are 
thus ionized, mass measured and fragmented by the mass spectrometer. The 
experimental dataset is subsequently identified by probability based scoring 
algorithms, e.g. Mascot [81]. In MS jargon, this is usually referred to as a 
“database search” or a “Mascot search” since it involves the automated 
matching of experimental data to theoretical peptide sequence data stored in a 
public database, e.g. Swiss-Prot or NCBInr. This type of proteomics 
experiment, also known as bottom-up proteomics [82], is a very powerful 
tool for identification of proteins in complex biological samples [83].  
In addition, various pre-analytical strategies may be applied to the common 
proteomics workflow for maximal analytical sensitivity. These include e.g. 
analysis of specific 1D or 2D SDS-PAGE bands/spots for characterization of 
individual proteins [84-86], enrichment of phosphorylated proteins for 
targeted phosphoproteomics [87, 88] or lectin affinity enrichment for 
identification of glycoproteins [89, 90].   
However, it should be stressed that the probability based scoring algorithms 
are primarily designed for identification of peptides, which are subsequently 
grouped into protein identities. Although simple modifications, e.g. 
phosphorylations, are readily identified in a database search [83], the 
probability based scoring algorithms are unable to resolve the structural 
complexity of glycans. Thus, even though glycoproteins per se may be 
identified, the protein linked glycans are not characterized by the common 
proteomics approach.  
Glycomics 
Glycomics is the systematic study of the glycan repertoire, i.e. the glycome, 
synthesized by a cell, tissue or organism under specific conditions. Although 
other technologies are available, the primary tool for analyzing the glycome 
is MS [91]. Most commonly, glycans are separated from their lipid- or 
protein components to allow high-throughput analysis. Protein linked O-
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glycans are usually released as alditols by reductive beta elimination [92, 93] 
whereas N-glycans are released by enzymatic peptide:N-glycosidase F 
(PNGase F) treatment [94-96]. Prior to MS analysis, released glycans may 
also be derivatized or labeled with various reagents to improve 
chromatographic separation or structural identification [97].  
A complete structural characterization of any glycan includes determining the 
size of the glycan, the identification of all monosaccharides included, their 
sequence (and possible branching), their relative linkage positions and 
determination of anomeric configurations of all the glycosidic bonds. For 
released glycans, reductive amination may be employed to couple 
fluorophores to glycans and thereby facilitate the quantification of the 
released glycoforms in each sample. Alternatively, gas chromatography-mass 
spectrometry (GC-MS) may be employed to obtain quantitative information 
on the molar ratios of individual monosaccharides in a sample. However, this 
technique requires the glycans to be hydrolyzed into monosaccharides prior 
to analysis. In addition, the hydrogen atoms of hydroxyl-, carboxyl- and 
amine groups may be replaced by methyl groups in a reaction known as 
permethylation. Tandem MS analysis of the permethylated glycans may yield 
detailed information on the linkage positions in individual glycans. 
Collectively, these techniques may thus yield qualitative and quantitative 
information on glycan composition and linkage positions. However, the 
anomeric configuration is not easily addressed by MS-based methods. One 
useful approach is to employ exoglycosidases to hydrolyze specific 
glycosidic bonds in a step by step manner. The digested glycans may 
subsequently be analyzed by GC-/LC-MS based methods. Alternatively, 
nuclear magnetic resonance (NMR) may be employed in order to characterize 
the absolute glycan structure but this technique requires large amounts of 
pure glycans and is thus not as sensitive as MS-based methods. 
Glycoproteomics 
In glycoproteomics, MS-based methods are used to elucidate not only 
glycoprotein identities but also to characterize glycan structures and pinpoint 
their protein attachment sites. This methodology is thus distinguished by the 
absolute requirement of intact glycopeptides for analysis. The combination of 
complex glycan structures on variable peptide sequences renders the 
glycoproteome orders of magnitude more complex than e.g. the glycome 
[98]. Consequently, glycoproteomic analysis may be considered even more 
challenging by comparison to proteomics or glycomics.  
Efficient enrichment of glycopeptides is a prerequisite in any glycoproteomic 
experiment. The primary pre-analytical task is thus elimination of non-
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glycosylated proteins. Equally important, the non-glycosylated tryptic 
peptides originating from glycoproteins must be removed to avoid analytical 
interference. Several different approaches have been used for this purpose 
[99, 100], including lectin affinity purification [101],  size-exclusion [102], 
and hydrophilic interaction liquid chromatography [103, 104]. However, 
these methods have generally been restricted to the studies of single 
glycoproteins and their applicability for glycoproteomic characterization of 
complex biological samples has not been shown.  
The identification of glycopeptides, i.e. their glycans, attachment sites and 
peptide sequences, is far from simple, even when a pure glycopeptide sample 
is analyzed. Algorithms or databases are not available for automated 
identifications, thereby leaving no other option but to annotate glycopeptide 
spectra manually [100]. Mucin-type O-glycopeptides are particularly difficult 
to analyze. In contrast to N-glycosylation, O-glycan attachment sites cannot 
be predicted by the primary amino acid sequence and require complementary 
fragmentation modes for identification. In addition, variable O-glycosylation, 
with respect to O-glycan density and structural heterogeneity, makes O-
glycopeptides exceptionally difficult to characterize [105, 106]. It is therefore 
not surprising that only a few glycoproteomic studies, aimed at analyzing 
glycopeptides from complex biological samples, have been published so far 
[107-109].  
Nevertheless, glycoproteomic characterization of biological samples is 
becoming increasingly important [110]. Although the combination of 
proteomics and glycomics is a powerful approach to study glycoproteins, a 
comprehensive understanding of glycoprotein structure and function also 
requires a detailed knowledge of the site-specific location of glycan 
structures. Given that aberrant glycosylation is associated with various 
pathological conditions [111-113], glycoproteomic investigation may also 
prove valuable for the discovery of novel biomarkers. This technique is 
therefore of central importance for further examination of glycoproteins in 
relation to health and disease. The section below provides a more detailed 
discussion on the biological fluids that we have used to explore the human 
glycoproteome.   
1.3 Cerebrospinal fluid 
Cerebrospinal fluid (CSF) is a clear and colorless fluid that surrounds the 
brain and the spinal cord. Although CSF is 99% water, it still contains a 
complex mixture of proteins, peptides and micronutrients (vitamin C and B6, 
folates etc.) [114]. In many ways, the composition of CSF is similar to blood, 
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with somewhat less glucose content and slightly higher concentration of 
NaCl. However, CSF is distinguished by the lack of cellular elements and 
relatively low protein content (~0.35 g/L) in comparison to blood. 
The majority of CSF is produced by the choroid plexuses (Fig. 4) through a 
dynamic process involving passive filtration, pinocytosis and active secretion 
[115, 116]. Newly produced CSF exits the third and fourth ventricle through 
three openings (median and lateral apertures) and enters the subarachnoid 
space to reach the cerebellomedullary- and pontine cisterns. Subsequently, 
CSF flows at about 0.35 mL/min through the subarachnoid space and over 
the surface of the brain towards the area of superior sagittal sinus. Most of 
the CSF is then absorbed back into the venous system at the point of 
arachnoid granulations [116].  The ventricular system and subarachnoid 
space contains approximately 140 mL CSF which is replaced three to four 
times each day. In other words, approximately 500 mL CSF is produced by 
the choroid plexuses during a 24 hour period.  
Choroid plexuses 
Pontine cistern 
Arachnoid granulations Superior sigittal 
sinus 
Subarachnoid 
space 
Third ventricle 
Fourth ventricle 
Cerebellomedullary 
cistern 
Figure 4. Cerebrospinal fluid excretion, circulation and reabsorption.  
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One basic function of CSF is to provide mechanical support by reducing 
(>30-fold) the effective weight of the brain. The buoyancy of this fluid also 
helps to absorb the shearing forces of acceleration generated during rapid 
head movements. Another important function of CSF is to transport 
macromolecules, e.g. transthyretin, insulin-like growth factor and thyroxine, 
to target neuronal cells and maintain a constant supply of micronutrients in 
circulation. Analogously, harmful metabolites are transported by CSF to the 
area of arachnoid granulations where they are absorbed back into the venous 
system. Also, CSF maintains the intracranial pressure in response to blood 
volume and retains a constant buffer reservoir of osmolytes which can be 
exchanged with the brain interstitial fluid to counteract increments in ion 
concentrations. In essence, CSF provides both a physical and a biochemical 
environment that is suitable for the brain and the spinal cord. 
The main fraction of CSF proteins is derived from serum by the action of 
pinocytosis across the capillary endothelium. Albumin alone constitutes 55-
75% of the total protein content in CSF, which, together with certain 
immunoglobulins (>15%), accounts for the dominating portion of the CSF 
proteome by mass [117]. However, secretory mechanisms of the choroid 
plexuses also release proteins that can be regarded as CSF-specific. The close 
proximity of CSF to the surrounding brain tissue allows products of protein 
catabolism or tissue degeneration to be regularly released into the CSF, 
resulting in a characteristic protein profile for CSF. Qualitatively, it is 
estimated that 56% of the proteome is CSF-specific since these proteins are 
not detected in the plasma proteome [118].  
Pathological conditions in the central nervous system (CNS) may alter the 
composition of CSF and cause changes in CSF protein profiles. Due to the 
close contact of CSF to the surrounding brain tissue, neuropathological 
conditions are more likely to be reflected in the CSF proteome than in other 
biological fluids, e.g. plasma or urine. CSF therefore provides a natural 
source for biomarkers that can be useful for diagnosing, predicting or 
monitoring the progression of diseases in the CNS.  
1.3.1 Alzheimer’s disease and APP 
Alzheimer’s disease (AD), first described by the Bavarian psychiatrist Alois 
Alzheimer in 1907 [119], is the most common form of age-related dementia. 
Approximately 20-30 million people worldwide are believed to be affected 
by dementia, of which AD accounts for 50-60% of all cases [120]. 
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AD is a progressive neurodegenerative disorder of the CNS which results in 
neuronal and synaptic loss in the cortical areas of the brain. The initial 
symptoms of mild cognitive decline, disorientation, impaired judgment and 
short term memory loss gradually intensify and ultimately results in 
dementia, which clinically defines AD. Neuropathological features of the 
AD-affected brain include extracellular deposition of amyloid plaques and 
intraneuronal neurofibrillary tangles. The latter are formed by 
hyperphosphorylation of the microtubule-associated protein tau, which 
induces self-assembly of tangles [121]. The extracellular amyloid plaques are 
mainly composed of aggregated amyloid beta (Aβ) peptides [122-124] which 
are derived from the amyloid precursor protein (APP) [125, 126].  
APP is a ubiquitously expressed type 1 transmembrane glycoprotein for 
which the precise physiological roles remain unknown. The catabolic Aβ 
peptides result from sequential proteolytic processing of APP by the action of 
α-secretase 
γ-secretase 
sAPPα 
Full-length APP 
p3 
α-CTF 
Non-amyloidogenic pathway 
…DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA… 
β 
1 
α γ 
10 17 42 
sAPPβ 
β-secretase 
γ-secretase 
Aβ1-42 
Full-length APP 
β-CTF 
Amyloidogenic pathway 
Figure 5. Proteolytic processing of APP by α-, β- and γ-secretases 
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α-, β- and γ-secretases (Fig. 5) [127-129]. In the amyloidogenic pathway, 
full-length APP is initially cleaved by β-secretase to release a soluble APP 
ectodomain (sAPPβ) while leaving a C-terminally truncated fragment (β-
CTF) in the membrane. The β-CTF is subsequently processed by 
intramembranous γ-secretase cleavage which liberates the 40-42 amino acid 
peptides (Aβ1-40 and Aβ1-42). The Aβ1-40 isoform is quantitatively more 
abundant in CSF but the two additional amino acids of Aβ1-42 enhance the 
hydrophobic character and amyloidogenic properties of this isoform. Aβ1-42 
is the major constituent in amyloid plaques but both variants can be detected 
in these aggregates. In the non-amyloidogenic pathway, full-length APP is 
cleaved by α-secretase to release the sAPPα ectodomain. The α-secretase 
cleavage occurs at amino acid 16 (numbering according to the Aβ sequence) 
and thereby precludes the formation of e.g. Aβ1-42. Instead, the following γ-
secretase cleavage results in formation of the p3 fragment (Aβ17-40/42) 
which is believed to be released into CSF. 
In addition to the processing pathways described above, APP/Aβ can undergo 
further proteolytic cleavages to yield alternative Aβ fragments in CSF [130-
132]. The β-CTF can be cleaved by α-secretase to give shorter Aβ1-X 
fragments (e.g. Aβ1-14/15) whereas alternative γ-secretase cleavage of β-
CTF can yield e.g. Aβ1-17/18/19/34/38 variants [133]. Cleavage of APP by 
the joint activity of α-secretase and other (unidentified) proteases can also 
produce endogenous APP/Aβ fragments that are N-terminally truncated 
upstream of the β-secretase cleavage site. These APP/Aβ fragments are 
typically cleaved at residues -57, -51 or -25 (relative to Asp1 of the Aβ 
sequence) and extend to Gln15 of the Aβ sequence [134]. Collectively, these 
are referred to as APP/AβX-15 fragments. 
Aβ peptides are constitutively produced at high levels under non-pathological 
conditions in humans. This process is normally counterbalanced by clearance 
mechanisms that eliminate Aβ species, e.g. Aβ1-42, from CSF [120]. These 
mechanisms include receptor-mediated transport across the blood-brain 
barrier (BBB) and proteolytic degradation of Aβ peptides by e.g. neprilysin 
(NEP).  
Twenty years ago, the amyloid cascade hypothesis was proposed as the 
initiating event in AD [135, 136]. According to this hypothesis, the intricate 
balance between Aβ production and clearance is disrupted, leading to the 
accumulation and aggregation of Aβ peptides (mainly Aβ1-42) which 
subsequently deposit as amyloid plaques. This process is believed to trigger 
the neuropathological changes, i.e. neuronal and synaptic loss, which 
ultimately results in cognitive dysfunction and dementia. 
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1.4 Urine 
Urine production by the kidneys produces a transparent, colorless to dark 
yellow fluid that contains a broad class of substances, e.g. electrolytes (salts), 
vitamins, amino acids and other organic compounds. Proteins and peptides 
are present but in significantly lower quantities by comparison to plasma or 
CSF. For healthy individuals, protein content in urine does usually not exceed 
0.1 g/L. Normal cellular activity, e.g. protein or intermediary metabolism, 
generates various metabolic end products that are constitutively released into 
the bloodstream. One important function of the kidneys is to prevent toxic 
build-up of such metabolic waste products through the process of urinary 
elimination. 
Twenty-five percent of the cardiac output, i.e. ~2000 L/day, is circulated and 
filtered in the kidneys. This process produces the primary urine, or 
glomerular filtrate (~180 L/day), of which 99% is reabsorbed in the kidneys 
before the final urine (~1.5 L/day) is excreted to the bladder [137].  
The formation of urine is precisely regulated by three distinct processes, i.e. 
glomerular filtration, tubular reabsorption and tubular secretion [138-140]. 
These processes occur in the nephrons (Fig. 6), which are the functional units 
of the kidney. Urine formation begins with the filtration of plasma at the 
Figure 6. Production of urine by the process of glomerular filtration, tubular 
reabsorption and secretion in the nephron. 
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glomerulus. The pores of the glomerular endothelium together with the 
basement membrane and the slit diaphragm structure form a semipermeable 
barrier in three levels (glomerular filtration barrier) that allows free passage 
of small molecules, e.g. H2O and electrolytes [140]. However, the passive 
filtration of large molecules (>60 kDa) and proteins, especially negatively 
charged proteins, is efficiently restricted by this barrier [141]. The glomerular 
filtrate subsequently flows from Bowman’s space into the proximal 
convoluted tubule where the majority of H2O, electrolytes, glucose, amino 
acids, peptides and proteins are reabsorbed. Organic acids, hydrogen ions and 
ammonia are simultaneously secreted into the fluid by the tubular cells. This 
dynamic process proceeds in each substructure of the loop of Henle, where a 
verity of substances are constitutively reabsorbed and secreted, either 
passively or actively, by the tubular cells. The distal convoluted tubule is 
relatively impermeable but is characterized by the ability to respond to 
hormonal stimulation. In the presence of e.g. antidiuretic hormone (ADH), 
the distal convoluted tubule responds by increasing the reabsorption of H2O 
and thereby functions to regulate the retention of H2O during dehydration 
[137]. During the flow towards the bladder, the collecting duct channels and 
continuously alters the composition of the fluid by reabsorption and secretion 
mechanisms. Ultimately, these complex processes produce the concentrated 
solution of metabolic waste products known as final urine. 
Although urinary elimination of proteins is limited by the nephrons, small 
amounts (<0.1 g/L) of urinary proteins can still be detected during normal 
physiological conditions [137]. This is attributed to several mechanisms, e.g. 
plasma proteins evading tubular reabsorption, tubular secretion of soluble 
proteins, detachment of GPI anchored proteins, exosome shedding or even by 
protein excretion from the prostate gland [141, 142]. The majority (70%) of 
urinary proteins originate from the kidneys and the urothelium whereas the 
remaining fraction (30%) is derived from the glomerular plasma filtrate 
[143].   
Urinary Proteomics 
The first proteomic study of healthy human urine dates back to 1997 where 
the combination of LC-MS and Edman degradation experiments identified 37 
protein fragments [144]. With the improvement of proteomic and 
bioinformatics tools, the number of identified proteins in healthy human urine 
reached approximately 800 by 2005 [142, 145-147]. The following year, a 
single study identified more than 1500 urinary proteins in healthy individuals 
[148]. The largest dataset for the urinary proteome, which includes more than 
2300 proteins identifications, was reported in 2009 [149]. Most recently, 
Mann and coworkers identified a common set of nearly 600 proteins in 
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healthy human urine which were defined as the “core urinary proteome”, i.e. 
proteins that are readily detectable in all studied individuals [150]. Notably, 
the 20 most abundant proteins, which account for nearly 70% of the core 
urinary proteome by mass, were all but one (serum albumin) found to be 
glycoproteins.  
During the past few years, proteomic strategies have also been applied to 
study the urinary proteome in relation to various disease states. Urinary 
protein biomarkers have been successfully identified not only for renal 
diseases but also for other disorders in distal organs [151]. Interestingly, 
glycoproteins are also overrepresented in the urinary panel of biomarkers 
[152].  
Proteomic analysis of urine remains analytically challenging mainly because 
of the dilute protein concentration and high content of interfering substances, 
i.e. salts, pigments and other metabolic waste products. Despite this fact, 
urine is still considered an important diagnostic medium for systemic and 
renal diseases. Furthermore, the complex protein composition of urine [148-
150] constitutes a challenging proteome not only for biomarker discovery but 
also for structural characterization of human glycoproteins.   
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2 AIM 
The general aim of this thesis was to develop glycoproteomic techniques for 
characterization of N- and O-linked glycopeptides. The specific aims were to: 
• Develop methods for efficient enrichment of N- and O-
linked glycopeptides originating from glycoproteins/peptides 
in complex biological samples (e.g. CSF and urine). 
 
• Utilize established proteomic LC-MS/MS techniques and 
bioinformatics tools for characterization of glycoproteins by 
identification of peptide sequences, glycan structures and 
their attachment sites.  
 
• Refine the sialic acid capture-and-release protocol to enable 
targeted O-glycoproteomics.  
 
• Conduct in-depth glycoproteomic analysis of targeted 
glycoproteins for structural as well as (semi)quantitative 
analysis of different glycoforms. 
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3 METHODS 
3.1.1 Sialic acid capture-and-release 
Capture of sialylated glycoproteins 
The glycopeptide enrichment strategy described in this thesis is based on two 
established facts: i) selective oxidation of sialic acids by periodate (IO4
-
) 
[153, 154] and ii) selective hydrolysis of sialic acid glycosidic bonds by mild 
acid treatment [155]. Periodate oxidation of cis-diols introduces aldehyde 
functionalities and, depending on the reaction conditions, vicinal hydroxyls 
of either sialic acids or monosaccharides in general may thus be converted to 
aldehydes. Aebersold and co-workers elegantly showed that serum 
glycoproteins, periodate oxidized under relatively harsh conditions (15 mM 
IO4
-
, RT, 60 min), may be coupled to a solid phase (hydrazide beads) via 
their aldehyde functionalities [156]. Inspired by this study, an alternative 
approach for targeted enrichment of sialylated glycoproteins was developed 
in this thesis (Fig. 7). The procedure involves selective oxidation of sialic 
Sialic acid Oxidized sialic acid 
Vicinal hydroxyl 
groups 
Aldehyde 
group 
Hydrazide beads 
Oxidized sialic acid 
Conjugated glycoprotein 
2 mM IO4
- 
0°C, 15 min 
pH 4.5 
RT, 16 h 
Figure 7. Capture of sialylated glycoproteins 
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acids by mild periodate treatment (2 mM IO4
-
, 0°C, 15 min) and coupling of 
oxidized sialic acids to hydrazide beads. The solid phase, conjugated with 
sialylated glycoproteins via stable hydrazone bonds, was subsequently 
washed to remove unbound proteins. Following reduction and alkylation, the 
conjugated glycoproteins were trypsin digested and the trypsin released 
peptide fraction was extracted for MS analysis. Consequently, tryptic 
glycopeptides, conjugated via sialylated glycans, were preserved on the 
hydrazide beads.  
Release of desialylated glycopeptides 
The solid phase was initially washed to remove residual non-glycosylated 
peptides. The sialic acid glycosidic bonds were hydrolyzed by mild acid 
treatment (0.1M formic acid, 80°C, 60 min) to release desialylated N- and O-
linked glycopeptides for MS analysis. The entire enrichment procedure, 
described in more detail in paper I, III and IV, is summarized in Fig. 8.   
Figure 8. Sialic acid capture-and-release for enrichment of sialylated 
glycoproteins and desialylated N-and O-linked glycopeptides. 
Biological sample Sialylated glycoproteins Sialylated glycopeptides 
Capture Trypsin 
Trypsin released 
peptides 
Mild acid 
hydrolysis 
MS analysis MS analysis 
Trypsin 
Formic acid 
released 
desialylated 
glycopeptides 
Targeting the human glycoproteome 
24 
3.1.2 MS analysis 
Glycoprotein identification 
Captured glycoproteins were identified by established proteomics methods 
[83]. Briefly, trypsin released peptide fractions were chromatographed 
(reversed-phase C18 column) and analyzed on-line by ESI-LTQ-FTICR. 
Precursor ions were mass measured by FTICR, isolated and subjected to 
collision induced dissociation (CID) to induce peptide fragmentation. This 
fragmentation technique is performed in the LTQ and involves the collision 
of precursor ions with neutral helium molecules. Upon collision, the kinetic 
energy is partially converted to internal energy (vibrational excitation) which 
ultimately leads to peptide backbone fragmentation (Fig. 9) into b- and y-type 
ions (nomenclature according to Roepstroff and Fohlman [157]). The 
experimental peptide fragments were identified and grouped into protein 
identities by the Mascot algorithm.   
Glycopeptide characterization by CID 
The key features of glycopeptide CID fragmentation have been discussed 
elsewhere [158]. In summary, glycopeptide MS
2
 spectra are characterized by 
abundant Y-type ions and diagnostic B-type oxonium ions (nomenclature 
according to Domon and Costello [159]) that arise from glycosidic bond 
fragmentations (Fig. 10). Peptide backbone fragments are usually not 
observed during CID MS
2
 of glycopeptides.  
Figure 9. Nomenclature of peptide N- and C-terminal fragments.  
Figure 10. Nomenclature for describing the fragmentation of glycans and glycopeptides. 
Y0 Y1 Y2 
B1 B2 B3 
Peptide 
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Here, an alternative MS strategy was employed in order to elucidate the 
primary structure of glycopeptides, i.e. both glycan- and peptide sequences. 
Glycopeptides were chromatographed and analyzed using the same MS 
platform as above. Precursor ions were mass measured by FTICR and 
fragmented by CID in the LTQ. Subsequently, the five most abundant 
fragment ions were isolated and subjected to additional rounds of CID-
fragmentation. In other words, an MS
2
 spectrum and five MS
3
 spectra were 
acquired for individual glycopeptides. N- and O-linked glycan sequences 
were manually identified by tracing the loss of monosaccharides from the 
peptide backbone. Selected MS
3
 spectra, corresponding to peptide backbone 
fragmentation, were identified by the Mascot algorithm.  
Glycopeptide characterization by ECD 
Electron capture dissociation (ECD) is an alternative technique for peptide 
fragmentation [160]. The principle of ECD, which is performed in the FTICR 
mass analyzer, is based on the reaction of multiply protonated precursor ions 
with low-energy electrons. In this process, electrons are captured by 
protonated peptides (M), resulting in the formation of peptide radicals (M•) 
that rapidly dissociate, before energy randomization occurs, into peptide c- 
and z-type fragments (Fig. 9) according to the reaction below.  
[M + nH]
n+
 + e
- 
→ [M + nH•](n-1)+ → fragmentation 
One characteristic feature of ECD is the ability to fragment the peptide 
backbone without disrupting labile glycosidic bonds. ECD may therefore be 
used for glycopeptide analysis and, in particular, for identification of O-
glycan attachment sites. This fragmentation technique was applied for the 
analysis of glycopeptides in paper II, III and IV. Electron transfer 
dissociation (ETD) is a similar fragmentation technique that is available on 
orbitrap instruments. This technique was applied for the analysis of O-
glycopeptides in paper IV.     
3.1.3 Targeted O-glycoproteomics 
The sialic acid capture-and-release method was further refined to allow 
targeted enrichment of O-linked glycoproteins and O-linked glycopeptides. 
Prior to glycopeptide enrichment, N-linked glycans were specifically 
removed by enzymatic PNGase F treatment. The sample was subsequently 
processed according to the sialic acid capture-and release procedure 
described above. This strategy was initially evaluated using a well-
characterized glycoprotein (bovine fetuin) and subsequently applied to a 
complex biological sample (CSF).  
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3.1.4 Glycoproteomics of APP/Aβ 
APP/Aβ peptides (including APP/Aβ glycopeptides) were 
immunoprecipitated according to the method developed by Portelius and co-
workers [131]. Briefly, the monoclonal 6E10 antibody (mouse IgG), specific 
for Aβ residues 4-9, was coupled to magnetic Dynabeads (Sheep anti mouse, 
IgG). Subsequently, 5 mL CSF was incubated with the magnetic beads to 
allow immunoprecipitation of Aβ peptides. The APP/Aβ peptides were eluted 
by 0.5% formic acid and evaporated to dryness prior to MS analysis. 
APP/Aβ peptides were dissolved and chromatographed on a reversed-phase 
C4 column. Precursor ions were mass measured by FTICR and characterized 
by CID and ECD fragmentation techniques. The MS data was annotated 
manually.    
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4 RESULTS 
4.1.1 Paper I 
The sialic acid capture-and-release method for enrichment of glycopeptides 
was initially evaluated using two model glycoproteins, i.e. human transferrin 
(TF) and bovine fetuin (FET). The efficient enrichment of tryptic N-
glycosylated peptides (N-glycopeptides) from TF is shown in Fig. 11A. The 
base peak ion chromatogram revealed three dominating peaks, eluting at 30-
40 min, which were mass measured by FTICR (Fig. 11B). The molecular ion 
masses were matched, with good mass accuracy (±10 ppm), to tryptic TF 
peptides with five Hex and four N-acetylhexosamine (HexNAc) units, 
tentatively assigned as desialylated biantennary complex type N-glycans. The 
peak at ~36 min (m/z 1028.5) appeared due to the deamination of the N-
terminal Cys residue. 
The glycan composition of each precursor ion was characterized by CID 
fragmentation (Fig. 11C). In CID-MS
2
, diagnostic B-type oxonium ions (m/z 
366 and m/z 528) and abundant Y-type fragments revealed structural 
information on the N-glycan sequence. The presence of relatively abundant 
Y1-type ions (m/z 840.9), corresponding to peptide+HexNAc fragments, was 
found to be a common feature during CID-MS
n
 of N-glycopeptides in 
Figure 11. MS analysis of sialic acid capture-and-release enriched glycopeptides. (A) Base 
peak ion chromatogram of transferrin N-glycopeptides. (B)FTICR MS of the molecular ion 
eluting at ~32 min. (C) CID-MS2 for N-glycan sequence analysis. (D) CID-MS3for peptide 
sequence analysis.    
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accordance with previous studies [100]. CID-MS
3
 fragmentation of Y1-type 
ions generated peptide backbone b- and y-type fragments (Fig. 11D) which 
were used to identify the peptide sequence (p<0.05 significance level) 
through the Mascot algorithm. Bovine fetuin was enriched and analyzed 
according to the same principle as above. All three N-linked glycopeptides of 
FET were characterized. In addition, three glycopeptides with HexHexNAc 
core 1-like O-glycans were identified (Supplemental data, paper I). Taken 
together, these experiments demonstrated that both N- and O-glycopeptides 
may be efficiently enriched by the sialic acid capture-and-release method. 
Also, the CID-MS
n
 approach was found to be a successful strategy for 
identifying both glycan and peptide sequences of N- and O-glycopeptides.  
Next, the sialic acid capture-and-release procedure was applied to a complex 
biological sample, i.e. CSF. Bottom-up proteomic analysis of the trypsin 
released peptide fraction (Fig. 8) identified 84 proteins, the majority of which 
were found to be glycoproteins. The base peak ion chromatogram of the 
formic acid released glycopeptide fraction was dominated by various N- and 
O-linked glycopeptides (Fig. 12A), showing that the sialic acid capture-and-
release method was applicable to complex biological samples.  
Figure 12. (A) Base peak ion chromatogram of sialic acid capture-and-release enriched 
glycopeptides from CSF. (B) CID-MS2 analysis for sequencing O-glycans. (C) CID-MS3 
spectrum of the Y0 fragment from panel B used for identification of the peptide sequence 
(cystatin C). 
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In total, 36 N- and 43 O-glycopeptides were characterized with respect to 
glycan and peptide sequences. The Hex5HexNAc4 composition, tentatively 
assigned as the biantennary complex type N-glycan structure, was found to 
be the most common glycoform of N-glycopeptides in CSF. The enriched O-
glycopeptides were only detected with core 1-like HexHexNAc O-glycans. 
The majority of these (37 unique peptides) were identified as new, previously 
unknown O-glycopeptides, e.g. the peptide from cystatin C (Fig. 12B-C).  
4.1.2 Paper II and IV 
In the follow-up study to paper I, the enrichment method was refined to allow 
targeted O-glycoproteomics of complex biological samples. Initially, PNGase 
F treated FET was enriched and analyzed according to the procedures 
described above. O-glycopeptides, but not N-glycopeptides, were identified 
in the following MS analysis (not shown). Subsequently, CSF was PNGase F 
treated and enriched by the sialic acid capture-and-release method. As 
expected, the base peak ion chromatogram (Fig. 13A) lacked the 
characteristic N-glycopeptide peaks observed in paper I and was instead 
dominated by a prominent peak at ~23 min (m/z 994, Apolipoprotein E O-
glycopeptide). The absence of CSF N-glycopeptides facilitated 
characterization of many low-abundant O-glycopeptides, e.g. the precursor 
ion (m/z 838) eluting at ~22  min (Fig. 13B). This precursor ion was 
identified as the APP peptide GLTTRPGSGLTNIK with 3 HexHexNAc core 
1-like O-glycans. The peptide sequence was found to be located 
approximately ~20 residues N-terminally to the β-secretase cleavage site of 
APP. 
CID-MS
n
 analysis revealed the majority of O-glycopeptides to be substituted 
with core 1-like HexHexNAc O-glycans. ECD analysis allowed the precise 
identification of O-glycan attachment sites (Fig. 13C). In total, 78 O-
glycopeptides, constituting 95 putative O-glycosylation sites, were 
characterized with respect to glycan and peptide sequences. The combination 
of CID and ECD fragmentation techniques pinpointed 67 HexHexNAc core 
1-like O-glycans to unique Ser/Thr attachment sites. This approach, discussed 
in more detail in paper IV, demonstrated that scarce O-glycopeptides are 
made accessible for glycoproteomic characterization by PNGase F treatment 
and sialic acid capture-and-release enrichment. In addition, a very interesting 
APP O-glycopeptide was identified which justified a more detailed, in-depth 
O-glycoproteomic analysis of this glycoprotein. 
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Figure 13. Targeted O-glycoproteomics of CSF. (A) Base peak ion chromatogram of 
sialic acid capture-and-release enriched O-glycopeptides. (B) CID-MS2 analysis of the 
APP O-glycopeptide at m/z 838. (C) ECD fragmentation of the precursor ion at m/z 838 
for identification of O-glycan attachment sites. 
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To achieve this, APP/Aβ peptides were immunoprecipitated from human 
CSF samples with the 6E10 antibody (paper II). Previously, this approach 
was used to identify various Aβ1-X and APP/AβX-15 peptides in CSF [131, 
132]. These results were successfully reproduced; 33 Aβ1-X peptides and 14 
APP/AβX-15 peptides were identified in the 6E10 immunoprecipitated CSF 
fractions by MS analysis. Co-eluting with specific APP/AβX-15 peptides, 
several molecular ions with mass increments corresponding to 
(Sia)2HexHexNAc and/or   (Sia)1-4(HexHexNAc)1-4 glycans were also 
observed. CID-MS
2
 analysis of these precursor ions corroborated the 
presence of sialylated core 1-like O-glycans on APP/AβX-15 peptides (Fig. 
4, paper II). The O-glycans were mapped, by CID and ECD analysis, to 
specific Thr residues located at positions -39, -21, -20 and -11 relative to 
Asp1 of the Aβ sequence. The GLTTRPGSGLTNIK sequence (Fig. 13), 
which constitutes the -23 to -10 region of APP/AβX-15 peptides, was thus 
confirmed to accommodate three sialylated core 1-like O-glycans at Thr(-21, 
-20 and -11). The attachment site for one of the APP/AβX-15 O-glycans, 
located at either Thr(-9) or Ser(-5), could not be determined. In all, 37 unique 
APP/AβX-15 O-glycopeptides were identified (Table S1, paper II).      
Next, the molecular ions co-eluting with the Aβ1-X peptides were 
investigated in more detail. Several precursor ions, with m/z values matching 
specific Aβ1-X peptides with (Sia)1-3HexHexNAc glycans, were observed in 
the FTICR mass spectra. Prominent Y-type fragments and characteristic B-
type oxonium ions verified the mono- (SA), di- (SA2) and trisialylated (SA3) 
HexHexNAc glycan sequences in the following CID-MS
n
 experiments. The 
SA3 glycoform (Fig. 14A) was found with the unusual disialosyl sequence, 
which occasionally also was observed in the lactonized form                     
(Fig. 1, paper II). These results indicated that the terminal Hex-linked 
structure was a Neu5Acα2-8Neu5Ac epitope. Additional structural 
heterogeneity associated with the SA3 glycoform included O-acetylation of 
the disialosyl epitope. In total, 27 unique Aβ1-X O-glycopeptides were 
identified (Table S1, paper II).  
The Aβ1-38 and Aβ1-40 peptide isoforms were the most abundant Aβ 
components of 6E10 immunoprecipitated CSF samples. However, these 
peptide isoforms were not observed as glycosylated. In fact, only C-
terminally truncated Aβ peptides, the longest being Aβ1-20, were found to be 
glycosylated.   
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Figure 14. Tandem MS analysis of Aβ1-17 glycopeptides. (A) CID-MS2 spectrum of the 
trisialylated glycoform. (B) ECD spectrum of the disialylated glycoform. The m/z 
expansion shows the critical c- and z-ions that pinpoint the glycosylation site to Tyr10. 
The isotopic peaks of the z8 fragment are resolved in the Inset.  
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In the following experiments, ECD was performed to verify the peptide 
sequences and the O-glycan attachment site of Aβ1-X glycopeptides. Given 
that Aβ1-20 (DAEFRHDSGYEVHHQKLVFF) contained only one possible 
glycan attachment site, it was naturally assumed that all Aβ1-X glycopeptides 
were glycosylated on Ser8. However, the ECD analysis clearly showed that 
the O-glycans were selectively attached to Tyr10 (Fig 14B). ECD 
fragmentation of the Aβ1-17 SA2 glycoform generated a continuous c3-c15 
and an uninterrupted z2-z11 ion series. The c8 (DAEFRHDS, m/z 975.43) 
and c9 (DAEFRHDSG, m/z 1032.45) fragment ions, which include Ser8 but 
exclude Tyr10, were observed without the mass of the SA2 O-glycan whereas 
e.g. c10 and c11 fragment ions were found to be glycosylated. From the 
opposite direction, the z8 (YEVHHQKL, m/z 992.94) and z9 
(GYEVHHQKL, m/z 1021.44) fragment ions, which include Tyr10 but 
exclude Ser8, were both observed with the mass of a SA2 O-glycan, clearly 
showing that Aβ1-17 is glycosylated at Tyr10. The glycans of other Aβ1-X 
glycopeptides, e.g. Aβ1-15, were also mapped to Tyr10 by ECD experiments 
(Fig. 2 and Fig. S4, paper II). Taken together, these results demonstrated that 
the glycan attachment site of Aβ1-X glycopeptides was Tyr10. Finally, the 
relative signal intensities of individual Aβ1-X peptides and Aβ1-X 
glycopeptides, normalized to the summed intensities of all Aβ peptides 
(except Aβ-42), was compared for AD (n=6) and non-AD patients (n=7). A 
relative increase, by a factor of 1.1 to 2.5, of glycosylated versus non-
glycosylated Aβ peptides was observed for the AD patients (Fig. 3, paper II).  
In summary, the glycoproteomic analysis of 6E10 immunoprecipitated CSF 
samples identified five unique sialylated core 1-like O-glycans in the vicinity 
of the β-secretase cleavage site of APP. In addition, a unique, trisialylated 
HexHexNAc O-glycan, was found to reside between the α- and β-secretase 
cleavage sites. Tyrosine, which represents a novel attachment site for 
sialylated O-glycans in mammalian proteins, was found to be the modified 
residue of Aβ1-X glycopeptides.   
4.1.3 Paper III 
In this study, the sialic acid capture-and-release method was applied to an 
alternative, but also more challenging, biological fluid, i.e. urine. Initially, 
efficient enrichment of urinary glycoproteins was hampered by the high 
content of reducing waste products interfering with the periodate oxidation. 
However, these interfering compounds were successfully removed by 
repeated dialysis of which one was in 1.5% SDS. Following glycopeptide 
enrichment, 58 N- and 63 O-glycopeptides, constituting 57 putative O-
glycosylation sites, were characterized by CID and/or ECD analyses. The 
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precise attachment site of 40 Ser/Thr linked core 1-like O-glycans was 
defined, of which 29 had not been previously reported. Tyrosine linked 
glycans were not observed for the urinary O-glycopeptides. In addition to 
Hex5HexNAc4-N-Asn modified glycopeptides, several other N-glycoforms 
were characterized, including branched and fucosylated sequences 
(dHex1Hex7HexNAc6-N-Asn), tentatively assigned as tetra-antennary N-
glycans. Structural O-glycan variation for specific O-glycopeptides was also 
observed, e.g. fucosylation of core 2-like sequences (Fig. 15) and secondary 
modifications (sulfation) of O-glycans. This study demonstrated that sialic 
acid capture-and-release enrichment, in combination with efficient protein 
purification techniques, may be used for glycoproteomic characterization of 
analytically challenging biologic samples.     
 
Figure 15. CID-MS2 analysis of the urinary AVAVTLQSH O-glycopeptide (protein YIPF3) 
substituted with a fucosylated core 2-like glycan.  
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5 DISCUSSION 
Glycoproteins, in contrast to DNA and nascent proteins, are secondary gene 
products synthesized by non-template driven processes. Thus, there are no 
biological blueprints for predicting the structural details of glycoproteins. 
Traditionally, researchers have relied on various analytical techniques, the 
primary being MS-based analysis, for structural characterization of 
glycoproteins. However, the analytical difficulties associated with the 
structural complexity of glycoproteins have obligated researches to adopt a 
certain degree of reductionism in their MS-based analyses [161].  
The standard analytical approach has been to separate glycans from proteins 
and analyzed these components individually by either glycomic or proteomic 
techniques. As with any other analytical approach, this type of reductionism 
has its own advantages and disadvantages. In glycomics, sensitive 
characterization of glycan structures is achieved but the site-specific location 
of these glycans and the identities of their protein carriers are lost. Similarly, 
hundreds of glycoproteins may be identified by proteomic analysis but this 
approach is unable to provide any information on the actual glycosylation 
status of the identified glycoproteins. In other words, the classical trade-off in 
MS-based analysis has been glycan structures versus glycoprotein identities.  
So far, MS-based strategies aimed at analyzing intact glycopeptides have 
generally been limited to the monoproteic approach, a definition recently 
used by Dodds et al. to describe the glycoproteomic analysis of single 
glycoproteins [161]. Using this approach, glycan structures and their 
attachment sites may be determined but this type of analysis is only 
applicable to simple glycoprotein mixtures.     
The lack of efficient enrichment procedures has been one of the primary 
obstacles in unbiased glycoproteomic analyses. Accordingly, one of the 
primary ambitions in this thesis was to develop methods capable of efficient 
enrichment of N- and O-glycopeptides for glycoproteomic characterization of 
complex biological samples. 
Sialic acid capture-and-release 
The glycopeptide enrichment strategy described in this thesis capitalizes on 
the characteristic chemistry of sialic acids. This strategy was chosen for one 
important reason; the oligosaccharides of secreted and membrane bound 
glycoproteins are frequently terminated with sialic acids (Fig 2). By 
specifically targeting the sialylated glycoproteome both N- and O-
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glycoproteins may thus be enriched. In contrast to lectin-based methods, 
which are limited by the binding specificity of the lectin(s), e.g. jacalin 
recognizing Galβ1-3GalNAcα-O- structures [107], this strategy is able to 
enrich N- and O-glycoproteins without being restricted to a particular sub-
class of sialylated glycans. However, the obvious disadvantage is that non-
sialylated structures, e.g. blood group antigen terminated O-glycans (Fig. 2) 
or high-mannose type N-glycans, are not enriched by this method.  
Given that aldehyde groups are rarely found on proteins or glycoproteins, 
mild periodate oxidation of sialic acids (Fig. 7) is a simple way of 
introducing reactive aldehyde functionalities which may be utilized for 
targeted enrichment of sialylated glycoproteins. Under these mild conditions, 
the periodate oxidation is specific [154], i.e. oxidation takes place primarily 
at the glycerol side chain (C7-C9) of sialic acids. By comparison to the 
procedure of Aebersold and co-workers [156], the mild periodate treatment is 
also non-destructive for the underlying glycan, i.e. the ring structure of the 
monosaccharides is preserved. However, biological modifications at the C7-
C9 hydroxyls of sialic acids, e.g. O-acetylation, preclude the mild periodate 
oxidation. In other words, an unmodified glycerol side chain is a prerequisite 
for the introduction of aldehyde functionalities. Thus, glycoproteins modified 
by e.g. terminal OAcNeu5Ac structures are inaccessible for enrichment by 
this procedure.   
The aldehyde groups of oxidized sialic acids react with hydrazide beads to 
form covalent hydrazide bonds that conjugate sialylated glycoproteins to the 
solid phase (Figs. 7 and 8). The covalent linkage confers a significant 
advantage over traditional enrichment strategies, e.g. HILIC or lectin-based 
methods, by allowing relatively harsh washing conditions (e.g. >1.5M NaCl, 
>1% SDS or >50% acetonitrile) to be employed. Such conditions are 
inapplicable to conventional enrichment strategies based on non-covalent 
interactions. Considerable reduction of sample complexity, i.e. removal of 
non-glycosylated proteins, with concomitant purification of sialylated 
glycoproteins is thus achieved by repeated washing of the solid phase.  
The following trypsin digestion of the conjugated glycoproteins fulfills two 
functions: i) it releases non-glycosylated peptides from the solid phase 
(which may be identified by proteomic methods) and ii) it generates tryptic 
glycopeptides on the solid phase. The enrichment method is thus compatible 
with proteomic strategies aimed at identifying sialylated glycoproteins in 
complex biological samples. In paper I and III, the trypsin released peptide 
fraction was analyzed by bottom-up proteomics (section 1.2.2) which 
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confirmed that glycoproteins are efficiently enriched by the sialic acid 
capture-and-release method (table S1, paper I and table S1, paper III).  
Trypsin digestion of the conjugated glycoproteins leaves behind covalently 
linked glycopeptides, which is beneficial for several reasons. Perhaps the 
most important reason is however that this procedure allows conjugated 
glycopeptides to be separated from non-glycosylated peptides by sequential 
washing of the solid phase. Thus, ion suppression of glycopeptides by co-
eluting non-glycosylated peptides, which may have a dramatic impact on the 
analytical sensitivity [162], is avoided in downstream MS analyses. Ion 
suppression of glycopeptides is one of the primary limitations in 
glycoproteomic analysis. In monoproteic glycoproteomics, the tryptic digest 
(peptides and glycopeptides) of purified glycoproteins is usually analyzed 
with or without additional enrichment at the glycopeptide-level. Although 
this strategy is successful for purified glycoproteins [163], the ion 
suppression effect exerted by non-glycosylated peptides becomes a 
significant issue for complex protein mixtures. A plausible explanation for 
the lack of unbiased glycoproteomic studies on biological samples might thus 
be attributed to the inability of conventional enrichment methods, based on 
non-covalent interactions, to efficiently separate non-glycosylated peptides 
from glycopeptides.  
The conjugated glycopeptides are subsequently released by mild acid 
treatment (Fig. 8). The release mechanism is specific for sialic acids [155], 
i.e. glycosidic linkages between sialic acids and penultimate 
monosaccharides, but not between dHex, Hex or HexNAc residues, are 
hydrolyzed. In other words, glycopeptides are released from the solid phase 
as desialylated species. Clearly, the loss of sialic acids during the release 
procedure is one of the primary limitations of this method. No conclusions 
may thus be drawn with respect to sialic acid heterogeneity, except for the 
fact that the glycopeptides were sialylated to some degree. However, the 
main advantage is the ability to isolate intact glycopeptides. By comparison, 
Aebersold and co-coworkers used PNGase F to release of formerly N-
glycosylated peptides [156]. Although the enzymatic release is specific and 
allows identification of the N-glycan attachment site (based on the 
conversion of Asn to Asp at the glycosylation site), this procedure removes 
the entire N-glycan and is only applicable to N-glycopeptides. In contrast, the 
mild acid treatment preserves the glycan structure and works equally well for 
both N- and O-glycopeptides.  
In short, the specificity of the enrichment procedure described in this thesis is 
defined by two steps: i) selective oxidation of sialic acids by mild periodate 
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treatment and ii) selective hydrolysis of sialic acid glycosidic bonds by mild 
acid treatment. Taken together, these steps enable selective enrichment of 
desialylated glycopeptides for MS analyses. Consistent with this statement, 
glycopeptides were indeed found to be the dominating components in the 
formic acid released fractions of transferrin (Fig. 11A), CSF (Figs. 12A and 
13A) and urine (Fig. S4, paper III) samples. Considering that transferrin 
alone is trypsinized into ~80 protein fragments, the appearance of three 
dominating peaks in the base peak chromatogram demonstrated the efficient 
enrichment of TF N-glycopeptides. Notably, even contaminants (β-2-
glycoprotein N-glycopeptides, m/z 1153.2, ~23 min, Fig. 11A) in the ≥98% 
pure TF sample were enriched. 
It should be stressed that a similar enrichment strategy, termed reverse-
glycoblotting, was independently developed by Nishimura and co-workers. In 
their initial approach, oxidized sialic acids of tryptic glycopeptides were 
conjugated to aminooxy-functionalized polymers via stable oxime bonds and 
released by trifluoroacetic acid treatment (hydrolysis of sialic acid glycosidic 
bonds) [164]. Although the chemistry is similar to the sialic acid capture-and-
release method, their initial study on mouse serum was relatively 
unsuccessful (only 6 N-glycopeptides identified). In 2010, an improved 
enrichment strategy, based on hydrazide chemistry, was reported by the same 
group [108]. In their refined method, release of sialylated glycopeptides by 
ice-cold 1M HCl was reported, along with the identification of 67 N-
glycopeptides from mouse serum. Thus, the unique release strategy of 
Nishimura and co-workers represents an alternative method for enrichment of 
sialylated glycopeptides. It is reasonable to believe that this strategy is also 
suitable for enrichment of sialylated O-glycopeptides but such data has not 
been presented by these authors.  
MS analyses  
The MS analyses described in this thesis were based on accurate FTICR mass 
measurements followed by tandem MS experiments utilizing primarily CID 
and ECD fragmentation techniques. Although these methods are powerful 
tools for qualitative studies on glycopeptides, MS analyses alone are unable 
to resolve the absolute structure of glycopeptides, at least not according to the 
procedures described in this thesis. Regardless of mass accuracy and 
resolution, a mass measurement of two stereoisomers (section 1.1.1) will 
always yield the same mass, e.g. the oxonium ions of GalNAc and GlcNAc at 
m/z 204. Similarly, the anomeric configuration, linkage position and 
monosaccharide identities of disaccharides will not be resolved by simple 
mass measurements. For example, the oxonium ions of LacNAc (Fig. 1) and 
core 1 (table 1) structures will both appear at m/z 366, even though these 
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disaccharides are structurally unique. This limitation, which is valid for both 
B- and Y-type fragments (Fig. 10), is recognized by the use of non-colored 
symbols for glycan annotations in this thesis.  
The CID-MS
n
 approach was utilized as the primary method for the 
identification of glycopeptides in unbiased glycoproteomic analyses. This MS 
strategy is based on the fact that glycans may be sequence in CID-MS
2
, 
where predominant fragmentation of glycosidic bonds is expected [158], 
followed by CID-MS
3
 of Y1- or Y0-type ions, where peptide b- and y-type 
fragmentations are induced. In other words, the CID-MS
2
 event is used to 
“deglycosylate” the peptide component whereas the CID-MS
3
 event is 
employed to fragment the peptide component itself. Selected CID-MS
3
 
spectra, with peptide specific b- and y-type fragments, may therefore be 
queried for protein identification by the Mascot algorithm. In this way, 
glycopeptides may be characterized and confidently identified by utilizing 
established proteomic platforms. However, since individual precursor ions 
are subjected to multiple fragmentations events, the duration of each CID-
MS
n
 experiment is relatively time-consuming by comparison to standard 
proteomic methods. Thus, the primary disadvantage of the CID-MS
n
 
approach is that fewer precursor ions are analyzed during each 
chromatographic time-frame.  
During the course of data analysis, we concluded that the Mascot algorithm 
was unable to identify specific O-glycopeptides enriched from CSF (paper I). 
By relaxing the search parameters to allow semitryptic O-glycopeptides to be 
considered in the database search, the Mascot algorithm successfully 
identified several peptides with C- or N-terminal non-tryptic ends, e.g. the 
R.GVEYVCCPPPGTPD.P peptide from Amyloid-like protein 1. The non-
tryptic C-terminus is most likely the result of the formic acid treatment, 
which is known to hydrolyze peptides at Asp residues [165]. Similarly, 
further relaxing the Mascot search by querying the NCBInr database, a 
redundant peptide sequence database which includes single-nucleotide 
polymorphisms (SNPs), allowed for the identification of the cystatin C O-
glycopeptide shown in Fig. 12. It was thereby concluded that relaxed 
database searches are beneficial in unbiased glycoproteomic analyses. 
Notably, the A.VSPATGSSPGKPPR.L semitryptic sequence (A→T 
mutation) was found to originate from the N-terminal part of cystatin C. This 
peptide stretch includes the VSPATG sequence, which normally is part of the 
signal peptide that is enzymatically removed during the maturation of 
cystatin C [166]. It is tempting to speculate that the A→T mutation allows a 
sialylated O-glycan to be introduced at the Thr residue which, in turn, alters 
the proteolytic processing of this protein. However, whether or not this is the 
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case remains to be investigated. Nevertheless, these results tend to suggest 
that sialylated O-glycans are able to suppress proteolytic processing of 
proteins, in agreement with previous studies [43]. 
Targeted O-glycoproteomics 
These interesting results inspired us to refine our enrichment strategy for 
targeted O-glycoproteomic analysis. As described above, this was achieved 
by including the PNGase F treatment prior to the sialic acid capture-and-
release enrichment of CSF (paper IV). The enzymatic release of N-glycans 
from CSF glycoproteins allowed for specific enrichment of O-glycopeptides 
(Fig. 13A). However, the most abundant O-glycopeptides (hemopexin, m/z 
862, m/z 771 and m/z 828, Fig. 12A) characterized in paper I were not 
recovered after the PNGase F treatment.  Presumably, the removal of N-
glycans affects the solubility of hemopexin and causes it to precipitate before 
the oxidized sialic acids of the O-glycopeptides react with the hydrazide 
beads. This limitation may be circumvented by performing the PNGase F 
digestion after the capture of sialylated glycoproteins (not shown).  
The removal of N-glycans, and thereby the analytical interference of N-
glycopeptides, resulted in the identification 95 putative O-glycosylation sites, 
of which 67 were mapped to unique Ser/Thr residues by combined CID, ECD 
and ETD analyses. By surveying the amino acid sequence surrounding the O-
glycan attachment sites, we noted that proline residues are prominent in the -
1, +1 and +3 positions relative to the glycosylated Ser/Thr residues. These 
results are in agreement with previous studies [167, 168] and may be used to 
improve current bioinformatics tool for predicting O-glycan attachment sites. 
Given that the majority of these O-glycopeptides were found to be modified 
with core 1-like HexHexNAc-O-Ser/Thr sequences, efforts were also made to 
automate the identification procedure for these O-glycopeptides (paper IV). 
Although still under development, this type of data analysis holds great 
potential for rapid identification of HexHexNAc glycosylated peptides, i.e. 
what might take weeks of manual annotation is automatically identified in 
less than five minutes by this procedure. However, the identification of 
peptide glycoforms exceeding the simple core 1-like is not easily automated. 
This area of research requires the combined efforts of bioinformaticians and 
glycobiologists if further progress is to be made.  
Recently, Clausen and co-workers presented a unique strategy for targeted O-
glycoproteomics of cell lines [109]. In their approach, zinc finger nuclease 
(ZFN) gene targeting of the molecular chaperone Cosmc (Fig. 3) was used to 
generate cells expressing the truncated Tn- and sialyl-Tn antigens. Following 
lectin affinity enrichment, more than 350 O-glycosylation sites were 
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identified by MS analyses. Although this method is limited to cell-based 
studies, the ZFN approach is presently the most efficient method for profiling 
O-glycan attachment sites in complex protein mixtures. Notably, only twelve 
of the O-glycan attachment sites reported in paper IV, including the three Thr 
O-glycosites in Fig. 13C, were found to be in common with this study. For 
the O-glycopeptides identified in paper III, only two O-glycosites were found 
to be in common with the study of Clausen and co-workers. This surprisingly 
low overlap tends to suggest that the O-glycoproteome might be larger than 
previously believed. 
Considering that APP is implicated in the disease progression of AD (section 
1.3.1), the APP O-glycopeptide identified by the targeted O-glycoproteomics 
approach (Fig. 13) was perhaps the most interesting finding in paper IV. The 
identified HexHexNAc-O-Thr glycans, located in proximity to the β-
secretase cleavage site of APP, provoked many speculations, including the 
possibility that additional O-glycans might be located in the immediate 
vicinity or even within the Aβ sequence itself. These questions were 
addressed by the glycoproteomic analysis of immunoprecipitated APP/Aβ 
peptides from CSF (paper II).  
Glycoproteomics of APP/Aβ  
Immunoprecipitation of APP/Aβ peptides was employed as an alternative 
approach to study the O-glycosylations of APP. One of the primary 
advantages of this method, by comparison to the sialic acid capture-and-
release enrichment, is the ability to analyze sialylated O-glycopeptides. 
Accordingly, 64 unique O-glycopeptides of variable peptide lengths, sialic 
acid heterogeneities, sialic acid modifications and site occupancies were 
characterized. The relative amounts of specific APP/AβX-15 peptides and 
glycopeptides were found to vary with respect to their glycosylation status, 
indicating that O-glycosylations may suppress the proteolytic processing of 
APP at e.g. the -25 region (Fig. S9, paper II). Potentially, this argument may 
also apply to the β-secretase enzyme (section 1.3.1).  
In addition to the O-glycosylations of APP/AβX-15 peptides, a unique 
trisialylated O-glycans was also found to reside within the Aβ sequence itself, 
but only on shorter Aβ1-X peptides, with X being equal to or less than 20. 
This tends to suggest that APP processing, in the presence of Aβ 
glycosylation, is altered, resulting in a shift towards the non-amyloidogenic 
pathway (section 1.3.1). This conclusion is supported by the lack of 
glycosylation on longer Aβ peptides, e.g. Aβ1-42. Most likely, the presence 
of a sialylated O-glycans within the Aβ sequence is able to influence the way 
Targeting the human glycoproteome 
42 
by which this region of APP is recognized and processed by α-, β- and γ-
secretases.    
The CID and ECD experiments also revealed that Aβ1-X peptides were 
glycosylated at Tyr10, in contrast to the anticipated Ser8. Given that 
sialylated O-glycans have previously only been described for Ser/Thr 
residues (section 1.1.2), the ECD analysis in Fig. 14B thus identified Tyr as a 
novel attachment site for sialylated O-glycans in human proteins.  
The most abundant Aβ1-X glycopeptides were calculated to be 10-30 pg/mL 
(100-200 pg/mL for the non-glycosylated variants), based on the signal 
intensity of an isotopic internal standard. In the context of analytical 
sensitivity, considerable depth, at the expense of breadth, was thus achieved. 
In the pilot study of AD and non-AD patients, a relative increase of Tyr10 
glycosylated versus non-glycosylated Aβ peptides was observed for the AD 
patients. Thus, the Tyr10 glycosylated Aβ peptides might be used as early 
indicators (biomarkers) for the progression of AD. However, the small 
patient groups are obviously the primary limitation of this study, and these 
results should be confirmed in larger prospective studies to establish Aβ 
glycopeptides as clinically useful biomarkers. Notably, Tyr10 glycosylated 
Aβ peptides were recently also identified in cat CSF (Brinkmalm et al., 
submitted manuscript). These findings indicate that the cellular machinery 
responsible for synthesizing complex tyrosine glycosylation may be present 
in all species belonging to the mammalian magnorder Boreoeutheria. Animal 
models may therefore be used not only for general studies on complex 
tyrosine glycosylations but also for AD-related studies on Aβ glycosylations.  
Aβ peptides are constitutively produced and eliminated during non-
pathological conditions (section 1.3.1) but it is still unknown why Aβ 
peptides, under certain conditions, precipitate into amyloid plaques in 
humans. Studies in murine models show that overexpression of human APP 
results in amyloid deposition whereas wild-type mice do not develop amyloid 
plaques with age [169]. The amino acid sequences differ only by 4% for 
human and murine APP and three of these residues are located within the Aβ 
sequence itself (R5→G, Y10→F and H13→R). Recently, Kummer et al. 
demonstrated that Tyr10 nitration of Aβ critically enhances the 
amyloidogenic properties of Aβ1-42 [170]. These authors argued that Tyr10 
nitration, resulting from inflammatory processes in the brain, might be 
responsible for some of the early events that trigger amyloid deposition. This 
may explain why human Aβ with Tyr10, and not murine Aβ with Phe10, 
precipitates into amyloid plaques in animal models. In keeping with this, it is 
interesting to note that the reactive properties of tyrosine residues are, to a 
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great extent, governed by the electron donating properties of the phenolic 
hydroxyl group. By comparison to the benzene ring of phenylalanine, the 
phenolic hydroxyl group renders tyrosine 1000 times more reactive in 
aromatic nitration [171]. The electron donating properties, and thereby the 
reactivity of the tyrosine residues, is also affected by substitutions at the 
phenolic hydroxyl group. It is therefore reasonable to believe that nitration of 
Aβ Tyr10 residues may, according to the same principle, also be suppressed 
by a glycan substituent at the phenolic hydroxyl group. This would indicate 
that Tyr10 glycosylation is beneficial and that the sialylated O-glycans might 
prevent the nitration, and thereby the subsequent precipitation, of Aβ 
peptides. However, further studies are required to verify these speculations.         
In mammals, carbohydrate modification of the Tyr hydroxyl group was 
previously only known for the glucosylation of glycogenin [172, 173]. 
However, the identification of a HexNAc-O-Tyr containing glycopeptide, 
originating from Nucleobindin 2, was also identified in the recent study of 
Clausen and co-workers [109]. Based on the lectin specificity of the ZFN 
approach, these authors concluded that the glycan identity is most likely 
GalNAc-O-Tyr. This may also apply to the Aβ glycopeptides, i.e. the 
HexNAc identity might be GalNAc-O-Tyr. However, further studies are 
required to elucidate the exact structure of these sialylated O-glycans.    
Urinary glycoproteomics 
The sialic acid capture-and-release strategy was also used for the enrichment 
of urinary N- and O-glycopeptides (paper III). Initially, the enrichment 
procedure was hampered by the presence of metabolic waste products in the 
urine samples (section 1.4). These metabolic waste products, responsible for 
quenching the mild periodate oxidation of sialic acids, were eventually 
removed by dialysis but only after the addition of 1.5% SDS. These results 
demonstrated that, although sialic acids may be selectively oxidized, an 
additional requirement, apart from non-modified C7-C9 hydroxyls, is the 
absence of metabolic waste products or other interfering compounds. 
Nevertheless, this issue might be avoided by efficient protein purification 
procedures.  
Following capture-and-release enrichment, 58 N- and 63 O-glycopeptides 
were identified by CID and ECD experiments. In contrast to O-glycopeptides 
from CSF, extensive glycan heterogeneity was observed for specific O-
glycopeptides enriched from the urine samples (Fig. 15). However, the MS 
analysis of the heterogeneous O-glycopeptides proved to be difficult for 
several reasons, including: i) the inability of B/Y-type ions to differentiate 
core 2-like glycans from elongated (linear) core 1-like glycans and ii) the 
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inability of Y-type fragments to differentiate peptides occupied by a single 
core 2-like glycan from peptides occupied by two individual core 1-like 
glycans. However, by combining the CID-MS
n
 data with the ECD data for 
the same precursor ions, complementary information could be gathered and 
used to differentiate these types of heterogeneous O-glycosylations. Although 
urinary O-glycopeptides were carefully analyzed, Tyr glycosylated peptides 
were not identified. These results suggest that complex tyrosine glycosylation 
is rare, and possibly more tissue specific, than mucin-type O-glycosylation on 
Ser/Thr residues.     
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6 CONCLUSION 
The overall goal of this thesis was to develop glycoproteomic techniques for 
characterization of N- and O-linked glycoproteins in complex biological 
samples. 
 
Due to the structural complexity of glycoproteins no single analytical 
technique is available for a complete structural characterization of any 
glycoconjugate. Thus, some kind of reductionistic approach is usually 
employed to simplify, automate and interpret the analyses. The basic 
analytical set-up is usually one of several variants of chromatography 
coupled to mass spectrometry, due to the excellent capacity for separation, 
speed, sensitivity, characteristic fragmentation and high mass accuracy of low 
to high molecular weight compounds. Traditionally, glycobiologists release 
from glycoproteins the glycans to fully characterize the glycome, whereas 
protein chemists and other biologists release the glycans to fully characterize 
the proteome. The ambition of this thesis has been to start bridging the two 
approaches in order to facilitate for both fields to incorporate knowledge 
from the other, simply asking the question which glycan is attached to which 
amino acid residue in a protein. Additionally, in order to cope with the large 
dynamic width of protein concentrations as well as their structural 
complexities in biological samples one or several efficient procedures are 
needed for enrichment or simplification of the mixture of glycoprotein 
isoforms subjected to analysis. Finally, the vast amount of data generated 
from the LC-MS/MS analyses must be handled, interpreted and made 
available for others to use. These aspects of glycoproteomic approaches are 
the cornerstones of this thesis.   
 
Terminal sialic acids are characteristically found on many oligosaccharides of 
glycoproteins and play important roles for the processing, halftime and 
biological functions of sialylated glycoproteins. From this standpoint and the 
relative ease to specifically oxidize the side chain of sialic acid residues and 
covalently couple them to hydrazide (beads), perform trypsin digestion of 
solid phase attached proteins and finally cleave the characteristically acid 
labile sialic acid glycosidic bond by mild acid treatment, we introduced a 
procedure for global characterization of sialylated glycoproteins. This sialic 
acid capture-and-release protocol was shown to be a successful approach for 
the efficient analysis of N- and O-glycopeptides derived from 
glycoproteins/glycopeptides in human cerebrospinal fluid and urine. The 
urine samples however, could not initially be treated simply according to the 
original protocol for oxidation of sialic acids, but needed extensive dialysis to 
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remove reducing agents. By also introducing a pretreatment step using 
PNGase F for enzymatic removal of N-linked glycans, prior to sialic acid 
oxidation, focus was put specifically onto the O-glycoproteome. Altogether 
66 glycoproteins and 131 glycosylation sites (36 N-linked and 95 O-linked) 
were identified from the CSF samples. The corresponding figures for urine 
samples were 53 glycoproteins and 82 glycosylation sites (25 N-linked and 
57 O-linked). The majority (45) of the O-glycosylation sites were previously 
unknown. 
 
Initially we analyzed all LC-MS/MS spectra manually but ultimately we were 
able to automate the procedures to export CID-MS3 peptide fragmentation 
peak lists together with the calculated peptide precursor mass into a Mascot 
file in order to simplify the identification of significant peptides. This 
automated analysis of spectra of O-glycopeptides should make our sialic 
acid-capture-and-release method more attractive also for other users. With 
increasingly more and more O-glycosylation sites being identified on human 
glycoproteins an opportunity was given to statistically analyze the residues 
surrounding the glycosylated Ser/Thr residues in order to identify possible 
glycosylation motifs. Indeed, we found that Thr/Ser/Pro residues in S/T-X-X-
P (45%), P-S/T (35%) and S/T-P (25%) glycosylation motifs were 
predominant features of the O-glycopeptides from CSF. 
 
Through the sialic acid targeted O-glycoproteomic analysis of CSF we 
identified glycopeptides in the vicinity of the β-secretase cleavage site of the 
amyloid precursor protein (APP). By specifically analyzing APP/Aβ 
fragments, immunoprecipitated from CSF, an in-depth glyco/proteomic 
analysis of APP was performed. This study confirmed the findings of a series 
of short Aβ1-X peptides but also revealed two completely novel series of O-
glycopeptides, one being APP/AβX-15 glycopeptides carrying up to 4 mono- 
or disialylated core 1 like O-glycans linked to Thr residues and the other 
being an Aβ1-X series of glycopeptides carrying one core l-like glycan with 
up to three sialic acid residues and uniquely linked to a specific tyrosine 
residue. Interestingly, in a small number of CSF samples from patients with 
Alzheimer disease or with mild cognitive impairment, the concentration of 
the latter series of glycopeptides was enriched relative to that of the Aβ 
peptides found in CSF. We were not able to identify any glycosylated form of 
the amyloidogenic Aβ1-42 in any of the samples. The pathobiological 
significance as well as the diagnostic potential of these findings still remains 
to be shown. 
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7 FUTURE PERSPECTIVES 
Although the work presented in this thesis has opened up some new strategies 
for future glycoproteomic studies there are still many technical challenges to 
tackle. 
 
Obvious limitations of our sialic acid capture-and-release protocol are e.g. 
that we do not enrich for non-sialylated structures and that we have so far 
cleaved off the sialic acids in the release protocol, thus loosing information 
on numbers of sialic acids and their positions in the enriched glycans. One 
strategy would be to refine the release mechanism to enable analysis of 
sialylated O-glycopeptides and thus address the issue of sialic acid 
heterogeneity in various glycoprotein isoforms. Additionally, the 
chromatographic systems that we have used are essentially taken only from 
standard proteomics LC-MS/MS protocols and have not been optimized for 
separation according to glycan but rather to peptide characteristics (i.e. 
hydrophobicity). The efficiency of protease digestion may also be challenged 
by using other enzymes to release glycopeptides of suitable length and 
composition. Finally there is a need to develop the LC-MS/MS analyses so 
that ions in the low mass region - or any ions of specific interest - are 
included in successive fragmentation cycles to yield optimal information on 
e.g. linkage positions and possibly monosaccharide identities. There is also a 
need to increase the sensitivity of the analyses to single-cell levels, to 
automate the procedures and to go from relative to absolute quantifications 
using isotopically labeled standards of glycopeptides. Finally, the 
bioinformatics handling of data should be improved from tedious manual 
interpretations, as used in the beginning of this thesis, to automated searches 
in relevant databases. Interactive systems for web based interpretation of MS 
data files should help in building reference based knowledge in the 
establishment of the field of glycoproteomics.  
 
Although limitations exist with the technology presented in this thesis there 
are certainly applications that call for activity. So far we have analyzed 
human CSF and urine samples but for making relevant comparisons with data 
already generated, it would certainly be interesting to analyze human plasma 
samples. In search for biomarkers and future diagnostic purposes plasma is 
generally considered the standard system for sampling and assaying. LC-
MS/MS analyses are well established in clinical laboratories but generally too 
slow and costly for standard assays and are usually complemented with 
antibody based easy access assays. However, there are no principal 
restrictions in the methodology presented not to analyze glycoproteins of 
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lysed cells and cell membranes. Such preparation may be taken from blood 
cells or from cell cultures. Of particular interest for us is to follow up our 
recent findings on the glycosylation of tyrosine in APP producing cells, of O-
mannosyl linked glycosylation of α-dystroglycan in differentiated muscle and 
nerve cells, as well as the importance of glycosylation of viral glycoproteins 
in cells facilitating virus propagation.    
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